NDAORALTABLET
Approved
Nov 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBUNOX is a fixed-dose oral combination tablet containing ibuprofen (a nonsteroidal anti-inflammatory drug) and oxycodone hydrochloride (an opioid analgesic). It is indicated for acute pain management, leveraging both anti-inflammatory and opioid mechanisms to provide enhanced analgesia. The combination allows for lower opioid doses while maintaining efficacy.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting a stabilizing or declining sales team focused on retention and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
COMBUNOX offers limited career growth opportunities due to its LOE-approaching status and zero linked job postings, making it unsuitable for those seeking dynamic commercial expansion. Professionals on this team should expect transition planning, consolidation, and potential redeployment as the product approaches generic competition.
Brand ManagerField Sales Representative
Worked on COMBUNOX at Forest Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.